Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Sold by Invesco Ltd.

Invesco Ltd. decreased its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) by 1.8% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 327,060 shares of the company’s stock after selling 5,845 shares during the period. Invesco Ltd. owned approximately 0.25% of Cytek Biosciences worth $2,123,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Charles Schwab Investment Management Inc. grew its position in Cytek Biosciences by 3.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,062,990 shares of the company’s stock valued at $6,899,000 after acquiring an additional 32,028 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Cytek Biosciences by 58.3% during the 4th quarter. JPMorgan Chase & Co. now owns 947,683 shares of the company’s stock valued at $6,150,000 after purchasing an additional 349,146 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Cytek Biosciences by 1.6% during the 4th quarter. Bank of New York Mellon Corp now owns 730,709 shares of the company’s stock worth $4,742,000 after buying an additional 11,665 shares during the period. Principal Financial Group Inc. lifted its holdings in Cytek Biosciences by 0.7% in the 4th quarter. Principal Financial Group Inc. now owns 506,925 shares of the company’s stock worth $3,290,000 after buying an additional 3,753 shares in the last quarter. Finally, Royce & Associates LP boosted its position in Cytek Biosciences by 159.6% in the 4th quarter. Royce & Associates LP now owns 470,819 shares of the company’s stock valued at $3,056,000 after buying an additional 289,425 shares during the last quarter. 69.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CTKB shares. Piper Sandler decreased their price target on shares of Cytek Biosciences from $8.50 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, March 4th. Stephens restated an “overweight” rating and issued a $6.00 target price on shares of Cytek Biosciences in a research note on Wednesday, March 19th. Finally, The Goldman Sachs Group set a $5.25 price target on Cytek Biosciences in a research note on Sunday, February 2nd.

Cytek Biosciences Stock Performance

Shares of CTKB opened at $3.75 on Wednesday. Cytek Biosciences, Inc. has a 1 year low of $3.27 and a 1 year high of $7.63. The firm has a fifty day moving average of $4.08 and a 200-day moving average of $5.34. The company has a market cap of $480.36 million, a price-to-earnings ratio of -46.87 and a beta of 1.41.

Cytek Biosciences Company Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.